American Portfolios Advisors Jounce Therapeutics, Inc. Transaction History
American Portfolios Advisors
- $2.36 Trillion
- Q3 2022
A detailed history of American Portfolios Advisors transactions in Jounce Therapeutics, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 1,650 shares of JNCE stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,650Holding current value
$0% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding JNCE
# of Institutions
4Shares Held
720KCall Options Held
0Put Options Held
0About Jounce Therapeutics, Inc.
- Ticker JNCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,694,200
- Description
- Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...